International agencies and organizations such as the Centre for Disease Prevention and Control, World Organization for Animal Health (OIE), and Food and Agriculture Organization have made major contributions toward reducing animal diseases and controlling and monitoring programmes for animal diseases. Various governments and international communities of public and private donors are providing funds for control and eradication programs. For instance, European Animal Health Strategy Programs have provided funding of US$ 1.48 billion from 2009 and 2014. Government organizations are focusing on the immunization of animals, which is expected to favour growth of the autogenous vaccines market.
Advancements in Biotechnology and Veterinary Science Propelling Market Growth
Particular focus on innovation to prevent and treat zoonotic diseases is creating a favorable environment for the growth of the autogenous vaccines market. Technological advancements in the field of biotechnology such as next-generation sequencing, synthetic biology, veterinary biologics, and others are expected to create a platform for the development of autogenous vaccines in high-income economies such as the U.K. and U.S. Further, continued investments in multi-disciplinary vaccinology research could improve vaccines and provide custom vaccines for animal infection.
Growing Antimicrobial Drug Resistance Boosting Demand for Autogenous Vaccines
Antimicrobial usage in both, farm and companion animals, has reduced in the last five years, due to government initiatives to restrict antimicrobial drug resistance (AMR) in animals and human beings. In this regard, veterinary vaccines reduce reliance on anthelmintic and antimicrobial drugs for treating infections, thus driving investments in parallel product categories such as autogenous vaccines for both, livestock and companion animals. Autogenous vaccines can help reduce the necessity for antibiotics by helping control infectious diseases in animal populations. This factor is expected to propel the growth of the global autogenous vaccines market.
North America and Europe to Lead Autogenous Vaccines Market
North America and Europe, together, hold around 65% share of the global autogenous vaccines market. Growing pet adoption rate, improving animal insurance policies, and increasing public animal health awareness are responsible for the growth of the autogenous vaccines markets in these regions. Increasing meat and dairy product consumption and stringent regulatory policies for animal vaccination in European and American countries are expected to propel the autogenous vaccines market.
Increasing Prevalence of Contagious Diseases to Create Demand for Customized Autogenous Vaccines
Animals are prone to an extensive range of contagious diseases such as pink eyes, peste des petits ruminants (PPR) or goat plague, a highly contagious disease that commonly affects ruminants. According to the Food and Agricultural Organization, peste des petits ruminants (PPR) virus can contaminate up to 90% of small ruminant inhabitants. Contagious disease outbreaks can severely disturb livestock production, resulting in direct and indirect financial losses. Government organizations along with public organizations share economic resources to prevent and control contagious infection in livestock, which is expected to fuel the growth of the global autogenous vaccines market during the forecast period.
Competitive Landscape of Autogenous Vaccines Market
Key players operating in the autogenous vaccines market across the globe include Boehringer Ingelheim International GmbH, Elanco Animal Health, Ceva (Ceva Biovac), Phibro Animal Health Corporation, and Dyntec s. r. o., among others. Manufacturers are focusing on mergers and acquisitions to expand their range of vaccines and strain types. For instance, in July 2019, Ceva Santé Animale ('Ceva') completed the acquisition of IDT Biologika GmbH ('IDT'), a veterinary biopharmaceutical company. Moreover, manufacturers are focusing on expansion and advancement of their production facilities and research centers to produce custom vaccines. For instance, in May 2017, Elanco Animal Health opened a new manufacturing facility for the manufacture of autogenous poultry vaccines in Winslow, Maine.
The research report on the autogenous vaccines market provides recommendations, overview of market, and estimations of market growth for the next decade. Increment in the number of veterinary vaccine manufacturers and increasing demand for custom autogenous vaccines are responsible for the growth of the market at an impressive rate. North America and Europe hold a substantial share of the global autogenous vaccines market. Increasing rare contagious diseases among animals, rising animal healthcare spending, and zoonotic disease eradication programs are all favoring the growth of the global autogenous vaccines market.
Autogenous Vaccines Market: Scope of the Report
Persistence Market Research (PMR) recently published a study on the global autogenous vaccines market. The study provides detailed assessment on key market dynamics, including the drivers, trends, opportunities restraints, and detailed information about the autogenous vaccines market structure. The market study presents exclusive information about how the autogenous vaccines market will grow during the forecast period of 2019-2029.
Key indicators of market growth, which include Year-on-Year (Y-o-Y) growth of the market and compounded annual growth rate (CAGR) are explained in PMR’s study in a comprehensive manner. Other information includes pricing analysis by region and by product type, which helps in deep understanding of the pricing details by researchers, suppliers, manufactures, and distributors. The other information contains volume analysis, which includes year wise growth of autogenous vaccines during the forecast period. This information can help readers understand the quantitative growth prospects of the autogenous vaccines market during the forecast period.
The study is relevant for manufacturers, suppliers, distributors, and investors, and can help them in developing appropriate strategies to grow in the market. Business researcher, shareholders, industry experts can leverage the information and data presented in PMR’s study.
The study also includes statistics as well as facts related to macroeconomics factors that are impacting developments in the market. It also offers actionable insights based on the future trends in the autogenous vaccines market. Furthermore, small businesses and new entrants in the autogenous vaccines market too can make use of the information presented in this study, based on which, they can make appropriate business decisions in order to gain momentum in the market.
Key Segments of Autogenous Vaccines Market
PMR’s study on the autogenous vaccines market offers information divided into three important segments — strain type, end user, and region. This report offers comprehensive data and information about the important market dynamics and growth parameters associated with these categories.
Key Questions Answered in PMR’s Autogenous Vaccines Market Report
Autogenous Vaccines Market: Research Methodology
In PMR’s study, a unique research methodology is utilized to conduct extensive research on the growth of the autogenous vaccines market, and reach conclusions on the future growth parameters of the market. This research methodology is a combination of primary and secondary research, which helps analyst ensure accuracy and reliability of conclusions.
Secondary resources referred to analyst during the production of the autogenous vaccines market study include statistics from government healthcare organizations, medicines journals, research journals, press release, annual reports, white papers, directories, and databases. Analysts have interviewed senior managers, product portfolio managers, CEOs, VPs, marketing/product managers, and market intelligence managers, who contributed to the development of this report as a primary resource.
Comprehensive information acquired from primary resources and secondary resources acts as a validation from companies in the autogenous vaccines market, and makes PMR’s projection on the growth prospects of the autogenous vaccines market more accurate and reliable.